Table 3.

Transplant outcomes for patients that underwent allogeneic stem cell transplantation (n = 202).

		Neutrophil engraftment	Platelet engraftment	Grades 2–4 acute GVHD	Chronic GVHD	Relapse at 4 years	NRM at 4 years	LFS at 4 years	OS at 4 years
MSDT (n = 61)	Pre-MRD neg (Group1, n = 48)	100% (95%CI, 100%)	97.9% (95%CI, 93.8–100%)	19.1% (95%CI, 7.9–30.3%)	56.5% (95%CI, 40.4–72.6%)	13.8% (95%CI, 1.6–26.0%)a	15.2% (95%CI, 4.6–25.8%)	71.0% (95%CI, 56.3–85.7%)b	77.6% (95%CI, 65.3–89.9%)c
	Pre–MRD pos (Group2, n = 13)	100% (95%CI, 100%)	100% (95%CI, 100%)	23.8% (95%CI, 0.1–47.5%)	38.3% (95%CI, 7.7–68.9%)	56.4% (95%CI, 15.8–97.0%)	7.7% (95%CI, 0–23.0%)	35.9% (95%CI, 2.0–69.8%)	35.9% (95%CI, 2.0–69.8%)
Haplo-HSCT (n = 141)	Pre-MRD neg (Group3, n = 100)	100% (95%CI, 100%)	90.1% (95%CI, 83.8–96.4%)	22.1% (95%CI, 13.9–30.3%)	44.9% (95%CI, 33.5–56.3%)	10.7% (95%CI, 3.8–17.6%)a	16.3% (95%CI, 9.0–23.6%)	72.3% (95%CI, 63.1–81.5%)d	75.7% (95%CI, 66.3–85.1%)e
	Pre-MRD pos (Group4, n = 41)	100% (95%CI, 100%)	94.9% (95%CI, 87.8–100%)	22.0% (95%CI, 9.3–34.7%)	38.5% (95%CI, 21.4–55.6%)	14.8% (95%CI, 3.6–26.0%)f	7.3% (95%CI, 0–15.3%)	77.7% (95%CI, 64.8–90.6%)g	80.5% (95%CI, 68.3–92.7%)h

^aP < 0.001 compared with the Pre-MRDpos MSDT group.

^bP = 0.024 compared with the Pre-MRDpos MSDT group.

^cP = 0.011 compared with the Pre-MRDpos MSDT group.

^dP = 0.043 compared with the Pre-MRDpos MSDT group.

^eP = 0.020 compared with the Pre-MRDpos MSDT group.

^fP = 0.021 compared with the Pre-MRDpos MSDT group.

^gP = 0.036 compared with the Pre-MRDpos MSDT group.

^hP = 0.027 compared with the Pre-MRDpos MSDT group.

MSDT, human leukocyte antigen matched sibling donor transplantation; haplo-HSCT, haploidentical stem cell transplantation; MRD, minimal residual disease; Pre-MRD pos, positive MRD status before transplantation; Pre-MRD neg, negative MRD status before transplantation; GVHD, graft-vs.-host disease; NRM= non-relapse mortality.